Oren Gilad
President, CEO at Aprea Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Aprea Therapeutics Inc., 3 years.
Aprea Therapeutics Inc.
Director · President/CEO
Chief executive roles
Aprea Therapeutics Inc.
· President, CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 23, 2024 | Aprea Therapeutics Inc. | Open-market purchase | +500 | $3.92 | $1,960 |
| Oct 15, 2024 | Aprea Therapeutics Inc. | Open-market purchase | +250 | $2.90 | $725 |
| Oct 14, 2024 | Aprea Therapeutics Inc. | Open-market purchase | +1,000 | $2.59 | $2,590 |
| Oct 10, 2024 | Aprea Therapeutics Inc. | Open-market purchase | +150 | $2.54 | $381 |
| Mar 28, 2024 | Aprea Therapeutics Inc. | Grant or award | +6,725 | — | — |
| Mar 13, 2024 | Aprea Therapeutics Inc. | Open-market purchase | +2,000 | $7.29 | $14,580 |
| Mar 9, 2023 | Aprea Therapeutics Inc. | Grant or award | +4,000 | — | — |
| Aug 23, 2022 | Aprea Therapeutics Inc. | Derivative conversion | +6,045,100 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.